EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026

Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026.
During a conference call on Thursday, March 26, 2026, at 10:00 a.m., CEO Dr. Dirk Pleimes and CBO Henner Kollenberg will present the financial results for the 2025 fiscal year, a review of key operational developments and milestones, and an outlook on Pentixapharm’s clinical and strategic priorities.
 

• Conference call on March 26, 2026, at 10:00 a.m. CET

To participate in the conference call, please register via the following link:
Registration for Pentixapharm Holding AG – FY 2025 Review & Management Outlook

About Pentixapharm Holding AG
Pentixapharm is a biopharmaceutical company with advanced clinical trials in the field of radiotherapeutics. Headquartered in Berlin, the company develops precision medicine diagnostics and therapeutics in the fields of oncology and cardiology with the aim of sustainably improving patient care.
 
For further information about Pentixapharm Holding AG please visit www.pentixapharm.com.